Partners will focus on specific cancer therapy.

Dako and Genentech have partnered to work on a new cancer diagnostic as a potential companion product for a specific Genentech investigational therapeutic. Dako, which has experience in developing cancer diagnostic tests, will assist in the identification of cancer patients who may receive greater benefits from a certain therapy.

According to Dako, the collaboration is in line with its ongoing strategy to combine its strengths with biotechnology and pharmaceutical companies to develop the offering of its Pharmacodiagnostic™ assays.

“We are very pleased to announce our collaboration with Genentech to potentially further expand the market for targeted therapies. We see a great potential in a strong collaborative approach between biotechnology and pharmaceutical companies and diagnostic companies in targeting the right drugs for the right patients, both to improve patient care and more efficiently manage healthcare costs,” says Patrik Dahlen, CEO and president of Dako Denmark .


Previous articleCellzome Receives $5M Grant from German Government
Next articleHarvard Medical School to Utilize Cellectricon’s Cellaxess HT System